Evidence map›Paper›PMID 33915030›Full record

ArticleProteomics. Clinical applications2021

Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease.

Eboni I Lance, Lisa M Faulcon, Zongming Fu, Jun Yang, Donna Whyte-Stewart, John J Strouse, Emily Barron-Casella, Kimberly Jones, Jennifer E Van Eyk, James F Casella and 1 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Proteomics. Clinical applications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Eboni I LanceDepartment of Neurodevelopmental Medicine, Kennedy Krieger Institute, Baltimore, Maryland, USA.
Lisa M FaulconFood and Drug Administration, Silver Spring, Maryland, USA.
Zongming FuDivision of Pediatric Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jun YangDivision of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Donna Whyte-StewartDivision of Pediatric Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
John J StrouseDivision of Pediatric Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Emily Barron-CasellaDivision of Pediatric Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Kimberly JonesDivision of Pediatric Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jennifer E Van EykDivision of Cardiology, Department of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
James F CasellaDivision of Pediatric Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Allen D EverettDivision of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins Medicine · USJohns Hopkins University · USCedars-Sinai Smidt Heart Institute · USDuke University · USUnited States Food and Drug Administration · US

Funding

Silent Cerebral Infarct Multi-Center Clinical TrialU01NS042804 · NINDS · WASHINGTON UNIVERSITY · PI DEBAUN, MICHAEL R. · 2003 to 2010
$20.7M
Sickle cell scholar componentU54HL090515 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CASELLA, JAMES F · 2008 to 2011
$3.8M
Clinical Hematology Research Development Program (K12) at Johns HopkinsK12HL087169 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CASELLA, JAMES F · 2006 to 2016
$3.7M
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate CancerU01CA214194 · NCI · EASTERN VIRGINIA MEDICAL SCHOOL · PI BOUTROS, PAUL CHRISTOPHER, KISLINGER, THOMAS · 2016 to 2021
$2.5M
Longitudinal SIT Trial Plasma Proteomic Biomarker Discovery and Validation in SCIR01HL091759 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CASELLA, JAMES F · 2008 to 2011
$1.6M
Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in ChildrenR34HL108756 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CASELLA, JAMES F, DEBAUN, MICHAEL R. · 2011 to 2014
$1.1M
Clinical and Neuroimaging Phenotypes of Neurodevelopmental Disorders inPediatric Sickle Cell DiseaseK23HL133455 · NHLBI · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LANCE, EBONI I · 2017 to 2020
$712k
CIHR PJT-162384NCI NIH HHS U01 CA214194NHLBI NIH HHS K12 HL087169NHLBI NIH HHS K23 HL133455NHLBI NIH HHS R01 HL091759NHLBI NIH HHS R34 HL108756NHLBI NIH HHS U54 HL090515NINDS NIH HHS U01 NS042804
6 · The paper itself

Abstract

purposeSickle cell disease (SCD) is an inherited hemoglobinopathy that causes stroke and silent cerebral infarct (SCI). Our aim was to identify markers of brain injury in SCD. EXPERIMENTAL

designPlasma proteomes were analyzed using a sequential separation approach of hemoglobin (Hb) and top abundant plasma protein depletion, followed by reverse phase separation of intact proteins, trypsin digestion, and tandem mass spectrometry. We compared plasma proteomes of children with SCD with and without SCI in the Silent Cerebral Infarct Multi-Center Clinical Trial (SIT Trial) to age-matched, healthy non-SCD controls.

resultsFrom the SCD group, 1172 proteins were identified. Twenty-five percent (289/1172) were solely in the SCI group. Twenty-five proteins with enriched expression in the human brain were identified in the SCD group. Neurogranin (NRGN) was the most abundant brain-enriched protein in plasma of children with SCD. Using a NRGN sandwich immunoassay and SIT Trial samples, median NRGN levels were higher at study entry in children with SCD (0.28 ng/mL, N = 100) compared to control participants (0.12 ng/mL, N = 25, p < 0.0004). CONCLUSIONS AND CLINICAL RELEVANCE: NRGN levels are elevated in children with SCD. NRGN and other brain-enriched plasma proteins identified in plasma of children with SCD may provide biochemical evidence of neurological injury.

Indexed as

Anemia, Sickle CellNeurograninProteomicsAdolescentBiomarkersChildChild, PreschoolFemaleHumansMaleProteomeBiomarkersNeurograninProteomeneurograninsickle cell diseasesilent cerebral infarctionstroke

Identifiers

PMID33915030
PMCPMC8666096
OpenAlexW3159228500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.